Johnson & Johnson (NYSE:JNJ) Releases FY25 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $10.50-10.70 for the period, compared to the consensus earnings per share estimate of $10.55. Johnson & Johnson also updated its FY 2025 guidance to 10.500-10.700 EPS.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $145.39 on Thursday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s fifty day moving average price is $148.10 and its two-hundred day moving average price is $156.05. The stock has a market capitalization of $350.04 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 earnings per share. As a group, analysts predict that Johnson & Johnson will post 9.95 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.41%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on JNJ shares. Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Barclays cut their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Finally, StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 17th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $173.20.

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.